|
| 37606673 | Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. | JAMA | 2023 |
| 34191971 | Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic. | Statistics in Biopharmaceutical Research | 2020 |
| 29768954 | Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications. | J Cardiovasc Pharmacol Ther | 2018 |
| 28304224 | Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. | N Engl J Med | 2017 |
| 28122070 | Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab. | JAMA Cardiol | 2017 |
| 26920601 | Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. | Am Heart J | 2016 |
| 24598985 | Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. | Eur Heart J | 2014 |
| 24161333 | AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). | J Am Coll Cardiol | 2014 |
| 24255061 | Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. | Circulation | 2014 |
| 23141812 | Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. | Lancet, The | 2012 |
| 23141813 | Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. | Lancet | 2012 |